tirzepatide surpass Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial 💡 New insight in diabetes

Important Safety Note: Eating before drinking reduces peak BAC but does not make any amount of alcohol safe to drive on

Hims & Hers' weight loss business continues to be a major focus for the company, and that segment is on pace to bring in $725 million in revenue in 2025, Yemi Okupe, Hims & Hers' chief financial officer, said during the Q3 call with investors in early November

Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ

While IV drips deliver glutathione directly into the bloodstream, they are expensive and the effects are often temporary

The RT-PCR test is positive in up to 60% [11, 86]

CJC-1295 and Ipamorelin are combined in therapy because they are known to work very well together